Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Fluorodeoxyglucose Uptake in Advanced Non-small Cell Lung Cancer With and Without Pulmonary Lymphangitic Carcinomatosis

HEAN OOI, CHING-YUAN CHEN, YU-CHUN HSIAO, WEN-SHENG HUANG and BOR-TSUNG HSIEH
Anticancer Research August 2016, 36 (8) 4313-4320;
HEAN OOI
1Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.
2Department of Preventive Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan, R.O.C.
3School of Medicine, Tzu Chi University, Hualien, Taiwan, R.O.C.
4Divisions of Pulmonology and Critical Care, Department of Internal Medicine, Dalin Tzu Chi Hospital, Dalin, Taiwan, R.O.C.
5Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHING-YUAN CHEN
6Department of Nuclear Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YU-CHUN HSIAO
6Department of Nuclear Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WEN-SHENG HUANG
7Departments of Nuclear Medicine, Taipei Veterans General Hospital and Tri-Service General Hospital, Taipei City, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wshuang01@gmail.com bthsieh@ctust.edu.tw
BOR-TSUNG HSIEH
1Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wshuang01@gmail.com bthsieh@ctust.edu.tw
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: To assess the correlation between advanced non-small cell lung cancer (NSCLC) with or without pulmonary lymphangitic carcinomatosis (PLC) and fluorodeoxyglucose (FDG) uptake and its effect on survival outcomes. Patients and Methods: We retrospectively reviewed 157 patients with NSCLC. The mean and maximum standardized uptake values (SUVmean and SUVmax, respectively), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were evaluated for their effect on overall survival (OS) and progression-free survival (PFS). Results: The PLC group included 55 patients and the non-PLC group included 102 patients. The SUVmean, SUVmax, MTV and TLG values were lower in the non-PLC group. In the PLC group, primary lung tumor TLG was a significant predictor of PFS, while whole-body TLG was found to be a significant predictor in non-PLC patients. Conclusion: Primary lung tumor TLG was a good predictor in PLC patients. Whole-body TLG could be a useful predictor only in patients without PLC.

  • Lung cancer
  • pulmonary lymphangitic carcinomatosis
  • fluorodeoxyglucose
  • prognosis

Pulmonary lymphangitic carcinomatosis (PLC) is defined as the dissemination of cancer into the lymphatic system in the lung. It is caused by cancer spreading from the pulmonary circulation into the interstitium of lung (1, 2). The invasion may be antegrade, spreading directly from the axial lymph node into the lung parenchyma, or retrograde, spreading from the lung periphery into the hilar lymph node (3). PLC may be localized to small areas of the lung or may be diffuse over larger areas and is often associated with advanced non-small cell lung cancer (NSCLC) (4).

The characteristic clinical diagnostic computed tomography (CT) features of PLC, which correlate with histopathologic findings, are an uneven thickening of the interstitial septa and bronchovascular bundles (5-7). The majority of studies using fluorodeoxyglucose-positron emission tomography (FDG-PET) in lung cancer patients have evaluated tumors and metastases based on the extent of FDG uptake, which correlates with tumor cell metabolism, measured by glucose uptake. High uptake reflects a high metabolic rate and increased tumor cell aggression. The degree of FDG uptake in tumors as seen on PET, which is determined by the mean standardized uptake value (SUVmean), maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG), is useful for predicting overall survival (OS) and progression-free survival (PFS) in lung cancer patients (8-11). However, the interpretation of these FDG uptake parameters in PLC has not been fully established. To our knowledge, 3 small case series have investigated the use of PET/CT for the detection of PLC (12-14), whereas no previous reports describing the differences in TLG uptake between PLC-positive and PLC-negative cases exist.

The purpose of this study was to assess the correlation between advanced NSCLC with or without PLC and FDG-PET/CT uptake and to evaluate its effect on survival outcomes.

Patients and Methods

Patient population. We retrospectively reviewed the medical charts of all patients with histopathologically confirmed NSCLC who underwent FDG-PET/CT at our institution, prior to lung cancer treatment, between January 2007 and December 2012. The histopathological confirmation of diagnosis was made using body fluid cytology, CT-guided biopsy or operative specimens. The median follow-up period was 13.5 months; all patients were followed up until the end of study on 31 December 2013. The inclusion criteria were as follows: (i) no known history of cancer, (ii) lung cancer that was staged using the American Joint Cancer Committee (AJCC) 2002/2010 criteria (5-7), (iii) the patient was evaluated according to institutional guidelines and (iv) the patient received subsequent clinical follow-up at our institution. The pretreatment work-up consisted of Eastern Cooperative Oncology Group (ECOG) performance status evaluation, clinical and physical examination, complete blood counts and biochemistry tests. The imaging studies included chest CT, chest radiography, brain magnetic resonance imaging (MRI)/CT and bone scintigraphy. Exclusion criteria were as follows: (i) no histopathologically confirmed NSCLC, (ii) a diagnosis of small cell carcinoma or bronchial adenoma, (iii) no FDG-PET/CT imaging prior to therapy, (iv) a history of cancer, (v) lung cancer not staged according to AJCC 2002/2010 criteria, (vi) lung cancer that was not diagnosed according to institutional guidelines, (vii) no subsequent clinical follow-up at our institution, (viii) administration of a steroid before the FDG-PET/CT examination and (ix) active tuberculosis, interstitial lung disease, pulmonary edema, opportunistic infection, radiation fibrosis and autoimmune disease/drug-induced lung disease.

Image analyses. CT scans were obtained according to the manufacturers' protocol using a General Electric HighSpeed or LightSpeed scanner (General Electric Medical Systems, Milwaukee, WI, USA). Intravenous contrast agent (100 ml) containing 300 mg/ml ioxilan was administered at a rate of 2 ml/s. Mediastinal (window width=350 Hounsfield units (HU), window level=40 HU) and lung (window width=1,500 HU, window level=2,600 HU) CT scans were obtained using a picture archiving and communication system (PACS). We retrospectively determined the presence of septal lines, bronchovascular thickening, ground-glass opacities, pulmonary nodules, lymphadenopathy and pleural effusions.

On chest CT images, if a primary lung cancer was noted, PLC was identified as uneven thickening of bronchovascular bundles, broad interstitial septal lines and a polygonal pattern in the interstitium. PLC was defined as diffuse if areas of the whole lung were involved and focal if localized to an interstitial line of one lung lobe. Other associated findings, such as lymphadenopathy, pleural effusion and nodules were also recorded (15). Two radiologists with 10 and 8 years of experience, respectively, independently assessed the images to diagnose PLC. Disagreements were resolved by discussion to reach a consensus interpretation.

Analysis of tumor volume in FDG-PET/CT. We used Volume Viewer software on a GE Advantage Workstation 4.4 (GE Healthcare, Milwaukee, WI, USA) to measure the tumor volume, which delineated the volume of interest using an automated SUV to provide an isocontour threshold. PET/CT parameters SUVmax, SUVmean and MTV were recorded. MTV was defined as the total computed tumor volume greater than the threshold SUV baseline as compared with the mediastinal background. SUVmean values plus 2 standard deviations are shown. The TLG was calculated from the product of MTV and SUVmean. These PET parameters were examined for normality and skewness, while log-squared transformation was applied to the skewed variables SUVmax, MTV and TLG (16-18).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patients' clinicopathological characteristics.

The study was approved by the Human Research Ethics Committee of our institution (Buddhist Tzu Chi General Hospital, Dalin; B10201023), with the need for informed consent being waived because of the retrospective nature of the study.

Statistical analyses. PFS was defined as the period extending from the date of FDG-PET imaging until disease recurrence or final follow-up and OS was defined as the period extending from the date of FDG-PET imaging until death or final follow-up.

For SUVmean, SUVmax, MTV and TLG, we selected cut-off values that maximized the profile partial likelihood in the Cox regression model. These were treated as binary explanatory variables, with their cut-off values determining positive or negative results. Patients were classified into low/high PET volume parameter groups for the whole-body and primary lung tumor, as described in previous volume parameter studies (19, 20). Accordingly, the cut-off values for the primary lung tumor were determined as 21.60 for SUVmean, 31.25 for SUVmax, 47.00 for MTV, and 330.00 for TLG. Those for the whole-body were determined as 22.00 for SUVmean, 41.25 for SUVmax, 30.82 for MTV and 383.29 for TLG.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Clinical factors and positron emission tomography data associated with and without pulmonary lymphangitic carcinomatosis in advanced non-small cell lung cancer patients.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Tumor size and histology associated with fluorodeoxyglucose (FDG) uptake in advanced non-small cell lung cancer patients.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Predictions of OS and PFS based on clinical factors and PET measurements in NSCLC patients with and without pulmonary lymphangitic carcinomatosis.

OS and PFS were calculated using the Kaplan-Meier method and groups were compared using the log-rank test. A multivariate analysis was performed using the Cox proportional hazards model to assess joint effects of the following variables on OS and PFS: age, sex, ECOG performance status, histology, treatment modality, SUVmean, SUVmax, MTV and TLG (relating to the primary tumor).

Results

Patients' characteristics. A total of 346 patients with histopathologically confirmed NSCLC were identified. A total of 157 patients met the inclusion criteria. The clinicopathological characteristics of patients are listed in Table I.

FDG-PET uptake in patients with and without PLC. Associations of PLC with clinical factors or PET measurements are shown in Table II and Table III. No clinical factors were significantly different between PLC and non-PLC groups. PET measurements were lower in the non-PLC group than in the PLC group, although only primary lung tumor TLG and whole-body TLG were significantly different between the groups with or without PLC (p=0.04 and p=0.01, respectively). In addition, tumor differentiation status and size were not significantly associated in between the groups with or without PLC. Survival analysis showed that the non-PLC group had longer median PFS and OS compared to the PLC group (p=0.03 and p=0.05, respectively).

Prognostic value of clinical factors and FDG uptake on survival. Clinical factors, such as age (>65 vs. <65 years) and treatment modality (chemotherapy vs. radiation/chemoradiation), were significantly associated with OS or PFS in the PLC and non-PLC groups (Table IV).

In patients with PLC, whole-body scan values of SUVmean, SUVmax and MTV were not significant prognostic factors. In contrast, in these patients, whole-body TLG and primary lung tumor TLG were significant prognostic factors for PFS. In patients without PLC, only whole lung TLG was a significant prognostic factor for PFS and OS, whereas whole-body SUVmax was a significant prognostic factor for PFS (Table V).

According to Kaplan-Meier estimates, in the PLC group, primary lung tumor TLG was significantly associated with PFS but not OS. In contrast, in the PLC group, whole-body TLG was not associated with survival (Figure 1). In the non-PLC group, primary lung tumor TLG was not associated with PFS or OS; however, whole-body TLG was significantly associated with both PFS and OS (Figure 2).

Discussion

Various neoplasms can cause PLC, although the most common cause is lung cancer (20, 21). PLC is associated with the movement of tumor emboli into the adjacent vessels or lymphatics. The engorgement of the lymphatics may compress the adjacent pulmonary vessels and blockage of the lymphatic system can cause the lymphatic bed surrounding the alveoli to become stiff, increasing the workload of the lungs and the breathing rate, which can lead to profound dyspnea in NSCLC patients with PLC. It is believed that tumor emboli account for the poor prognosis in advanced NSCLC patients with PLC (22, 23).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table V.

Association between OS and PFS in the PLC and non-PLC groups analyzed by Cox regression analysis.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Kaplan–Meier estimates of OS and PFS for the PLC group. (a) OS in the PLC group did not correlate with primary lung TLG (log rank test, p=0.41) (b) PFS in the PLC group correlated with primary lung TLG (log-rank test, p=0.04). (c) OS in the PLC group did not correlate with whole-body TLG (log-rank test, p=0.92). (d) PFS in the PLC group did not correlate with whole body TLG (log-rank test, p=0.51). OS, Overall survival; PFS, progression free survival; PLC, pulmonary lymphangitic carcinomatosis; TLG, total lesion glycolysis.

The current study showed that increased diffuse FDG uptake in the lungs correlated with the CT pattern of PLC, that was concordant with previous studies (12-14). For example, Digumarthy et al. showed that the FDG uptake pattern in 7 patients with PLC was the same as that on chest CT (14).

To our knowledge, there have been no prior publications reporting MTV, TLG or SUVmax in advanced NSCLC patients with PLC. Although Prakash et al. reported that the SUVmean in patients with PLC was significantly greater than that in patients without PLC (12), the authors analyzed SUVmean alone. Recent studies have demonstrated that MTV, TLG and SUVmax are significantly better predictors than SUVmean (24-26). In the current study, FDG uptake values (SUVmean, SUVmax, MTV and TLG) were lower in patients without PLC. In addition, there was a significant difference in primary lung tumor and whole-body TLG between patients with or without PLC. Primary lung tumor TLG was a predictor of PFS in patients with PLC, whereas whole-body TLG was a predictor of PFS and OS in patients without PLC.

Prognostic factors of lung cancer have been studied extensively, including clinical factors, such as tumor stage, age, treatment and ECOG performance status (27-29). In the current study, clinical factors, such as age and treatment modality, were significantly associated with OS or PFS in both the PLC and non-PLC groups. However, treatment modality was the only significant predictor of OS among patients with PLC.

This study has several limitations. First, we used a percentage threshold (i.e. 50% of SUVmax) to compute the tumor volume; we compared the value with the background of fused CT images, irrespective of whether any adjustment of the threshold was needed (30, 31). The choice of this threshold influences the tumor volume measurements; however, there is no consensus on how to delineate tumor volume and, thus, validation of this method is needed for future studies. Second, inflammation, especially in granulomatous changes, could also affect FDG uptake in the lung. However, to minimize this, we excluded any patients with active tuberculosis, interstitial lung disease, pulmonary edema, opportunistic infection, radiation fibrosis or drug-induced lung disease. Third, this was a retrospective study with a limited number of patients. A further large, prospective, randomized, multicenter study is needed to validate the findings of this report.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Kaplan–Meier estimates of OS and PFS for the non-PLC group. (a) OS in the non-PLC group did not correlate with primary lung TLG (log rank test, p=0.35). (b) PFS in the non-PLC group did not correlate with primary lung TLG (log rank test, p=0.19). (c) OS in the non-PLC group correlated with whole lung TLG (log-rank test, p=0.01). (d) PFS in the non-PLC group correlated with whole lung TLG (log-rank test, p=0.03). OS, Overall survival; PFS, progression free survival; PLC, pulmonary lymphangitic carcinomatosis; TLG, total lesion glycolysis.

Conclusion

In conclusion, the data suggest that an assessment of primary lung tumor TLG would be useful for predicting among patients with PLC. However, whole-body TLG could be useful for predicting only in patients without PLC. The different risk group (PLC or non-PLC) should be having a different predicting tool.

Acknowledgements

This study was performed at the Taichung Tzu Chi Hospital, Taiwan, ROC. The Authors thank the Department of Nuclear Medicine and the Cancer Center for their technical help and general support. This work was in part supported by grant MOST 103-2314-B-371-004-MY3.

  • Received June 14, 2016.
  • Revision received July 4, 2016.
  • Accepted July 5, 2016.
  • Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Hendin AS,
    2. Deveney CW
    : Postmortem demonstration of abnormal Deep pulmonary lymphatic pathways in lymphangitic carcinomatosis. Cancer 33: 1558-1563, 1974.
    OpenUrlPubMed
  2. ↵
    1. Green N,
    2. Kern W,
    3. Levis R,
    4. Schleiter W,
    5. Bonorris J,
    6. Berne CJ
    : Lymphangitic carcinomatosis of the lung: pathologic, diagnostic and therapeutic considerations. Int J Radiat Oncol Biol Phys 2: 149-153, 1977.
    OpenUrlPubMed
  3. ↵
    1. Band PR,
    2. Lentle BC,
    3. Amy R,
    4. Urtasun RC,
    5. Herbert FA
    : Radiologically occult pulmonary lymphangitic carcinomatosis detected by 67gallium-citrate scintiscan. Ann Intern Med 85: 476-477, 1976.
    OpenUrlPubMed
  4. ↵
    1. Ikezoe J,
    2. Godwin JD,
    3. Hunt KJ,
    4. Marglin SI
    : Pulmonary lymphangitic c arcinomatosis: chronicity of radiographic findings in long-term survivors. AJR AJR Am J Roentgenol 165: 49-52, 1955.
    OpenUrl
  5. ↵
    1. Munk PL,
    2. Müller NL,
    3. Miller RR,
    4. Ostrow DN
    : Pulmonary lymphangitic carcinomatosis: CT and pathologic findings. Radiology 166: 705-709, 1988.
    OpenUrlCrossRefPubMed
    1. Stein MG,
    2. Mayo J,
    3. Müller N,
    4. Aberle DR,
    5. Webb WR,
    6. Gamsu G
    : Pulmonary lymphangitic spread of carcinoma: appearance on CT scans. Radiology 162: 371-375, 1987.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Johkoh T,
    2. Ikezoe J,
    3. Tomiyama N,
    4. Nagareda T,
    5. Kohno N,
    6. Takeuchi N,
    7. Yamagami H,
    8. Kido S,
    9. Takashima S,
    10. Arisawa J
    : CT findings in lymphangitic carcinomatosis of the lung: correlation with histologic findings and pulmonary function tests. Am J Roentgenol 158: 1217-1222, 1992.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Chen HH,
    2. Chiu NT,
    3. Su WC,
    4. Guo HR,
    5. Lee BF
    : Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 264: 559-566, 2012.
    OpenUrlCrossRefPubMed
    1. Zaizen Y,
    2. Azuma K,
    3. Kurata S,
    4. Sadashima E,
    5. Hattori S,
    6. Sasada T,
    7. Imamura Y,
    8. Kaida H,
    9. Kawahara A,
    10. Kinoshita T,
    11. Ishibashi M,
    12. Hoshino T
    : Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy. Eur J Radiol 81: 4179-4184, 2012.
    OpenUrlCrossRefPubMed
    1. Park SB,
    2. Choi JY,
    3. Moon SH,
    4. Yoo J,
    5. Kim H,
    6. Ahn YC,
    7. Ahn MJ,
    8. Park K,
    9. Kim BT
    : Prognostic value of volumetric metabolic parameters measured by [18F] Fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. Cancer Imaging 14: 2, 2014.
    OpenUrlPubMed
  8. ↵
    1. Kahraman D1,
    2. Holstein A,
    3. Scheffler M,
    4. Zander T,
    5. Nogova L,
    6. Lammertsma AA,
    7. Boellaard R,
    8. Neumaier B,
    9. Dietlein M,
    10. Wolf J,
    11. Kobe C
    : Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non–small cell lung cancer treated with erlotinib. Clin Nucl Med 37: 1058-1064, 2012.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Prakash P,
    2. Kalra MK,
    3. Sharma A,
    4. Shepard JA,
    5. Digumarthy SR
    : FDG PET/CT in assessment of pulmonary lymphangitic carcinomatosis. Am J Roentgenol 194: 231-236, 2010.
    OpenUrlCrossRefPubMed
    1. Acikgoz G,
    2. Kim SM,
    3. Houseni M,
    4. Cermik TF,
    5. Intenzo CM,
    6. Alavi A
    : Pulmonary lymphangitic carcinomatosis (PLC): spectrum of FDG-PET findings. Clin Nucl Med 31: 673-678, 2006.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Digumarthy SR,
    2. Fischman AJ,
    3. Kwek BH,
    4. Aquino SL
    : Fluorodeoxyglucose positron emission tomography pattern of pulmonary lymphangitic carcinomatosis. J Comput Assist Tomogr 29: 346-349, 2005.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Stein DL,
    2. Freeman LM
    : Lymphangitic spread of breast carcinoma: scintigraphic pattern with chest x-ray and computed tomography correlation. Clin Nucl Med 9: 615-616, 2005.
    OpenUrl
  12. ↵
    1. Zhang H,
    2. Wroblewski K,
    3. Pu Y
    : Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer. Acta Radiol 5: 561-568, 2012.
    OpenUrl
    1. Liao S,
    2. Penney BC,
    3. Zhang H,
    4. Suzuki K,
    5. Pu Y
    : Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer. Acad Radiol 1: 69-77, 2012.
    OpenUrl
  13. ↵
    1. Yu HM,
    2. Liu YF,
    3. Hou M,
    4. Liu J,
    5. Li XN,
    6. Yu JM
    : Evaluation of gross tumor size using CT, 18F-FDG PET, integrated 18F-FDG PET/CT and pathological analysis in non-small cell lung cancer. Eur J Radiol 1: 104-113, 2009.
    OpenUrl
  14. ↵
    1. Yoo J,
    2. Choi JY,
    3. Lee KT,
    4. Heo JS,
    5. Park SB,
    6. Moon SH,
    7. Choe YS,
    8. Lee KH,
    9. Kim BT
    : Prognostic significance of volume-based metabolic parameters by 18F-FDG PET/CT in gallbladder carcinoma. Nucl Med Mol Imaging 46: 201-206, 2012.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Moon SH,
    2. Hyun SH,
    3. Choi JY
    : Prognostic significance of volume-based PET parameters in cancer patients. Korean J Radiol 14: 1-12, 2013.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Homsi S,
    2. Milojkovic N,
    3. Mesologites T,
    4. Homsi Y,
    5. Dasanu CA
    : Squamous cell lung cancer presenting with pulmonary lymphangitic carcinomatosis. J Ark Med Soc 107: 132-134, 2010.
    OpenUrlPubMed
  17. ↵
    1. Moubax K,
    2. Wuyts W,
    3. Vandecaveye V,
    4. Prenen H
    : Pulmonary lymphangitic carcinomatosis as a primary manifestation of gastric carcinoma in a young adult: A case report and review of the literature. BMC Res Notes 5: 638, 2012.
    OpenUrlPubMed
  18. ↵
    1. Gonzalez-Vitale JC,
    2. Garcia-Bunuel R
    : Pulmonary tumor emboli and cor pulmonale in primary carcinoma of the lung. Cancer 5: 2105-2110, 1976.
    OpenUrl
  19. ↵
    1. Soares FA,
    2. Pinto AP,
    3. Landell GA,
    4. de Oliveira JA
    : Pulmonary tumor embolism to arterial vessels and carcinomatous lymphangitis. A comparative clinicopathological study. Arch Pathol Lab Med 8: 827-831, 1993.
    OpenUrl
    1. Obara P,
    2. Pu Y
    : Prognostic value of metabolic tumor burden in lung cancer. Chin J Cancer Res 25: 615-622, 2013.
    OpenUrlPubMed
  20. ↵
    1. Ooi H,
    2. Chen CY,
    3. Hsiao YC,
    4. Huang WS,
    5. Hsieh BT
    : Influence of thyroid transcription factor-1 on fluorodeoxyglucose uptake and prognosis of non-small cell lung cancer. Anticancer Res 34: 2467-2475, 2014.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Chung HW,
    2. Lee KY,
    3. Kim HJ,
    4. Kim WS,
    5. So Y
    : FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lungadenocarcinoma. J Cancer Res Clin Oncol 1: 89-98, 2014.
    OpenUrl
    1. Pauwels EK,
    2. Coumou AW,
    3. Kostkiewicz M,
    4. Kairemo K
    : 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography imaging in oncology: initial staging and evaluation of cancer therapy. Med Princ Pract 5: 427-437, 2013.
    OpenUrl
  22. ↵
    1. Sengupta A,
    2. Banerjee SN,
    3. Biswas NM,
    4. Jash D,
    5. Saha K
    : The incidence of hyponatraemia and its effect on the ECOG performance status among lung cancer patients. J Clin Diagn Res 7: 1678-1682, 2013.
    OpenUrlPubMed
  23. ↵
    1. Cook GJ,
    2. Yip C,
    3. Siddique M,
    4. Goh V,
    5. Chicklore S,
    6. Roy A,
    7. Marsden P,
    8. Ahmad S,
    9. Landau D
    : Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med 1: 19-26, 2013.
    OpenUrl
  24. ↵
    1. Vesselle H,
    2. Schmidt RA,
    3. Pugsley JM,
    4. Li M,
    5. Kohlmyer SG,
    6. Vallires E,
    7. Wood DE
    : Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron-emission tomography. Clin Cancer Res 6: 3837-3844, 2000.
    OpenUrlAbstract/FREE Full Text
    1. Kluge S,
    2. Braune S,
    3. Nierhaus A,
    4. Wichmann D,
    5. Derlin T,
    6. Mester J,
    7. Klutmann S
    : Diagnostic value of positron-emission tomography combined with computed tomography for evaluating patients with septic shock of unknown origin. J Crit Care 27: 316.e1-e7, 2012.
    OpenUrlPubMed
    1. El-Haddad G,
    2. Zhuang H,
    3. Gupta N,
    4. Alavi A
    : Evolving role of positron-emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 4: 313-329, 2004.
    OpenUrl
PreviousNext
Back to top

In this issue

Anticancer Research: 36 (8)
Anticancer Research
Vol. 36, Issue 8
August 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Fluorodeoxyglucose Uptake in Advanced Non-small Cell Lung Cancer With and Without Pulmonary Lymphangitic Carcinomatosis
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
12 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Fluorodeoxyglucose Uptake in Advanced Non-small Cell Lung Cancer With and Without Pulmonary Lymphangitic Carcinomatosis
HEAN OOI, CHING-YUAN CHEN, YU-CHUN HSIAO, WEN-SHENG HUANG, BOR-TSUNG HSIEH
Anticancer Research Aug 2016, 36 (8) 4313-4320;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Fluorodeoxyglucose Uptake in Advanced Non-small Cell Lung Cancer With and Without Pulmonary Lymphangitic Carcinomatosis
HEAN OOI, CHING-YUAN CHEN, YU-CHUN HSIAO, WEN-SHENG HUANG, BOR-TSUNG HSIEH
Anticancer Research Aug 2016, 36 (8) 4313-4320;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The Systemic Inflammation Score Is an Independent Prognostic Factor for Esophageal Cancer Patients who Receive Curative Treatment
  • Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma
  • Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study
Show more Clinical Studies

Similar Articles

Keywords

  • Lung cancer
  • pulmonary lymphangitic carcinomatosis
  • fluorodeoxyglucose
  • prognosis
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire